Back to Journals » OncoTargets and Therapy » Volume 12

A significant response to a combination of trastuzumab and vinorelbine in HER2-negative metastatic breast cancer with HER2 V777L mutation

Authors Lei L, Ye W, Zheng L, Huang P, Shi L, Huang J, Zheng Y, Chen Z, Wang X, Wang X

Received 30 December 2018

Accepted for publication 26 February 2019

Published 17 April 2019 Volume 2019:12 Pages 2931—2936

DOI https://doi.org/10.2147/OTT.S199931

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Aruna Narula

Peer reviewer comments 2

Editor who approved publication: Dr Federico Perche


Lei Lei,1,2,* Wei-Wu Ye,2,* Lin-Feng Zheng,3 Ping Huang,2 Lei Shi,2 Jian Huang,2 Ya-Bing Zheng,2 Zhan-Hong Chen,2 Xiao-Jia Wang,2 Xian Wang1

1Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China; 2Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China; 3Department of Pathology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China

*These authors contributed equally to this work

Abstract: Metastatic breast cancer (MBC) is the most life-threatening disease in women worldwide. HER2-mutated breast carcinoma has been reported to benefit from HER2-targeted tyrosine kinase inhibitors recently. Here, we presented a heavy pretreated and harbored HER2 V777L mutation de novo stage IV Luminal B (HER2 unamplified) breast cancer patient who achieved an unexpected good response to trastuzumab combined with vinorelbine therapy. Although HER2-unamplified MBC patients do not regularly benefit from anti-HER2 target therapy, HER2 V777L mutation detected by next-generation sequencing from ctDNA may present as a predictive biomarker for anti-HER2-based strategy therapy in HER2-negative MBC patients.

Keywords: metastatic breast cancer, HER2 gene mutation, trastuzumab


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]